{
    "Trade/Device Name(s)": [
        "Premier C. difficile GDH"
    ],
    "Submitter Information": "Meridian Bioscience, Inc.",
    "510(k) Number": "K110620",
    "Predicate Device Reference 510(k) Number(s)": [
        "K030992"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "MCB"
    ],
    "Summary Letter Date": "March 2, 2011",
    "Summary Letter Received Date": "March 3, 2011",
    "Submission Date": "March 01, 2011",
    "Regulation Number(s)": [
        "21 CFR 866.2660"
    ],
    "Regulation Name(s)": [
        "Microorganism differentiation and identification device"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Clostridium difficile glutamate dehydrogenase antigen"
    ],
    "Specimen Type(s)": [
        "Fecal",
        "Human stool"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ELISA microplate",
        "Spectrophotometer",
        "StatFax 2200 Incubator/Shaker (optional)",
        "Semiautomated Microplate Washer (optional)"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Control",
        "Microwell",
        "Buffer",
        "Diluent",
        "Solution"
    ],
    "Document Summary": "FDA 510(k) summary for Premier C. difficile GDH qualitative enzyme immunoassay to detect C. difficile antigen in stool specimens",
    "Indications for Use Summary": "Qualitative enzyme immunoassay screening test for detection of Clostridium difficile antigen, glutamate dehydrogenase, in fecal specimens from symptomatic persons suspected of C. difficile infection; positive results require follow-up testing for toxigenic strains",
    "fda_folder": "Microbiology"
}